\n \nComposition \n \nORBAS 20: Each film-coated tablet contains Olmesartan Medoxomil INN 20 mg. \n \nORBAS 40: Each film-coated tablet contains Olmesartan Medoxomil INN 40 mg. \n \nIndication \n \nORBAS?(Olmesartan Medoxomil) is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents. \n \nDosage & Administration \n \nAdult \n \nHypertension \n \nThe usual starting dose of ORBAS (Olmesartan Medoxomil) is 20 mg once daily. Dosing should be individualized. Depending on the blood pressure response, the dose may be increased after 2 weeks to 40 mg. ORBAS (Olmesartan Medoxomil) may be administered with or without food. \n \nNo initial dosage adjustment is recommended for elderly patients, for patients with moderate to marked renal impairment (creatinine clearance < 40 mL/min) or with moderate to marked hepatic dysfunction. \n \nIf blood pressure is not controlled by ORBAS (Olmesartan Medoxomil) alone, a diuretic may be added. ORBAS (Olmesartan Medoxomil) may be administered with other antihypertensive agents. \n \nPediatric Hypertension (6 to 16 years of age) \n \nThe usual recommended starting dose of ORBAS (Olmesartan Medoxomil) is 10 mg once daily for patients who weigh 20 to < 35 kg or 20 mg once daily for patients who weigh > 35 kg. For patients requiring further reduction in blood pressure after 2 weeks of therapy, the dose may be increased to a maximum of 20 mg once daily for who weigh < 35 kg or 40 mg once daily for patients who weigh > 35 kg. \n \n